Deutsche Bank Upgrades Novo Nordisk to Buy
Deutsche Bank analyst Emmanuel Papadakis upgrades Novo Nordisk (NYSE:NVO) from Hold to Buy.
Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand
Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.
36 Stocks To Watch After Biden’s First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress.
ICER’s Report Suggests Benefits Of Eli Lilly’s Tirzepatide Not Better Than Other Diabetes Drugs
Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.
Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved
Novo Nordisk A/S (NYSE: NVO)
Novo Nordisk: Q4 Earnings Insights
Novo Nordisk (NYSE:NVO) reported its Q4 earnings results on Wednesday, February 2, 2022 at 01:30 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For February 2, 2022
Companies Reporting Before The Bell
• Sony Group (NYSE:SONY) is likely to report quarterly earnings at $1.57 per share on revenue of $24.59 billion.
UPDATE: Novo Nordisk Says Settlement Contains No Admission Of Liability, No Payment Will Be Made By Co.
https://ml-eu.globenewswire.com/Resource/Download/c1b1db85-fa01-448d-af99-4dd7acfcfcfa
FDA Concerns At Catalent Site Spurred Novo Nordisk’s Wegovy Supply Woes: Report
Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) o
If You Invested $100 In This Stock 5 Years Ago, Here’s How Much You Would Have Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 9.53% on an annualized basis.